v3.26.1
Segment, Geographic and Other Revenue Information - Revenues by Products (Detail) - USD ($)
$ in Millions
 3 Months Ended
Mar. 29, 2026
Mar. 30, 2025
Revenue from External Customer [Line Items]    
Revenues: $ 14,451 $ 13,715
Alliance revenues 2,339 2,113
Biopharma [Member]    
Revenue from External Customer [Line Items]    
Revenues: [1] 14,161 13,441
Biopharma [Member] | U.S. Commercial Division [Member]    
Revenue from External Customer [Line Items]    
Revenues: 7,686 7,572
Biopharma [Member] | International Commercial Division [Member]    
Revenue from External Customer [Line Items]    
Revenues: 5,233 4,849
Biopharma [Member] | Global Hospital and Biosimilars Division [Member]    
Revenue from External Customer [Line Items]    
Revenues: [2] 1,242 1,020
Pfizer CentreOne [Member]    
Revenue from External Customer [Line Items]    
Revenues: [3] 289 273
Total Alliance revenues [Member]    
Revenue from External Customer [Line Items]    
Alliance revenues 2,339 2,113
Royalty [Member]    
Revenue from External Customer [Line Items]    
Royalty revenue 396 308
Primary Care [Member] | Biopharma [Member]    
Revenue from External Customer [Line Items]    
Revenues: 5,542 5,692
Primary Care [Member] | Eliquis [Member] | Biopharma [Member]    
Revenue from External Customer [Line Items]    
Revenues: [4] 2,166 1,923
Primary Care [Member] | Prevnar Family [Member] | Biopharma [Member]    
Revenue from External Customer [Line Items]    
Revenues: 1,690 1,660
Primary Care [Member] | Nurtec ODT/Vydura [Member] | Biopharma [Member]    
Revenue from External Customer [Line Items]    
Revenues: 353 248
Primary Care [Member] | Comirnaty [Member] | Biopharma [Member]    
Revenue from External Customer [Line Items]    
Revenues: 232 565
Primary Care [Member] | Paxlovid [Member] | Biopharma [Member]    
Revenue from External Customer [Line Items]    
Revenues: 186 491
Primary Care [Member] | Abrysvo [Member] | Biopharma [Member]    
Revenue from External Customer [Line Items]    
Revenues: 180 131
Primary Care [Member] | FSME-IMMUN/TicoVac [Member] | Biopharma [Member]    
Revenue from External Customer [Line Items]    
Revenues: 81 63
Primary Care [Member] | All other Primary Care [Member] | Biopharma [Member]    
Revenue from External Customer [Line Items]    
Revenues: 654 609
Specialty Care [Member] | Biopharma [Member]    
Revenue from External Customer [Line Items]    
Revenues: 2,939 2,616
Specialty Care [Member] | Vyndaqel family [Member] | Biopharma [Member]    
Revenue from External Customer [Line Items]    
Revenues: 1,602 1,486
Specialty Care [Member] | Xeljanz [Member] | Biopharma [Member]    
Revenue from External Customer [Line Items]    
Revenues: 180 128
Specialty Care [Member] | Zavicefta (Outside the U.S. and Canada) [Member] | Biopharma [Member]    
Revenue from External Customer [Line Items]    
Revenues: 150 135
Specialty Care [Member] | Enbrel (Outside the U.S. and Canada) [Member] | Biopharma [Member]    
Revenue from External Customer [Line Items]    
Revenues: 138 140
Specialty Care [Member] | Octagam [Member] | Biopharma [Member]    
Revenue from External Customer [Line Items]    
Revenues: 122 88
Specialty Care [Member] | Genotropin [Member] | Biopharma [Member]    
Revenue from External Customer [Line Items]    
Revenues: 93 95
Specialty Care [Member] | Cibinqo [Member] | Biopharma [Member]    
Revenue from External Customer [Line Items]    
Revenues: 76 58
Specialty Care [Member] | All other Specialty Care [Member] | Biopharma [Member]    
Revenue from External Customer [Line Items]    
Revenues: 579 486
Oncology [Member] | Biopharma [Member]    
Revenue from External Customer [Line Items]    
Revenues: 3,826 3,494
Oncology [Member] | Ibrance [Member] | Biopharma [Member]    
Revenue from External Customer [Line Items]    
Revenues: 1,008 977
Oncology [Member] | Padcev [Member] | Biopharma [Member]    
Revenue from External Customer [Line Items]    
Revenues: 591 426
Oncology [Member] | Xtandi [Member] | Biopharma [Member]    
Revenue from External Customer [Line Items]    
Revenues: [5] 444 458
Oncology [Member] | Lorbrena [Member] | Biopharma [Member]    
Revenue from External Customer [Line Items]    
Revenues: 305 222
Oncology [Member] | Inlyta [Member] | Biopharma [Member]    
Revenue from External Customer [Line Items]    
Revenues: 214 219
Oncology [Member] | Adcetris [Member] | Biopharma [Member]    
Revenue from External Customer [Line Items]    
Revenues: [6] 190 218
Oncology [Member] | Braftovi/Mektovi [Member] | Biopharma [Member]    
Revenue from External Customer [Line Items]    
Revenues: [7] 174 136
Oncology [Member] | Bosulif [Member] | Biopharma [Member]    
Revenue from External Customer [Line Items]    
Revenues: 129 151
Oncology [Member] | Tukysa [Member] | Biopharma [Member]    
Revenue from External Customer [Line Items]    
Revenues: 122 102
Oncology [Member] | Orgovyx [Member] | Biopharma [Member]    
Revenue from External Customer [Line Items]    
Revenues: [8] 109 76
Oncology [Member] | Elrexfio [Member] | Biopharma [Member]    
Revenue from External Customer [Line Items]    
Revenues: 80 60
Oncology [Member] | Talzenna [Member] | Biopharma [Member]    
Revenue from External Customer [Line Items]    
Revenues: 50 40
Oncology [Member] | Tivdak [Member] | Biopharma [Member]    
Revenue from External Customer [Line Items]    
Revenues: 33 33
Oncology [Member] | All other Oncology [Member] | Biopharma [Member]    
Revenue from External Customer [Line Items]    
Revenues: 376 377
Hospital and Biosimilars [Member] | Biopharma [Member]    
Revenue from External Customer [Line Items]    
Revenues: [1] 1,854 1,639
Hospital and Biosimilars [Member] | Oncology Biosimilars [Member] | Biopharma [Member]    
Revenue from External Customer [Line Items]    
Revenues: [9] 409 264
Hospital and Biosimilars [Member] | Sulperazon (Outside the U.S. and Canada) [Member] | Biopharma [Member]    
Revenue from External Customer [Line Items]    
Revenues: 199 164
Hospital and Biosimilars [Member] | Inflectra [Member] | Biopharma [Member]    
Revenue from External Customer [Line Items]    
Revenues: 182 153
Hospital and Biosimilars [Member] | Zithromax [Member] | Biopharma [Member]    
Revenue from External Customer [Line Items]    
Revenues: 112 158
Hospital and Biosimilars [Member] | All Other Hospital and Biosimilars [Member] | Biopharma [Member]    
Revenue from External Customer [Line Items]    
Revenues: $ 953 $ 901
[1] In the first quarter of 2026, we made changes in our commercial structure, which included the transition of certain off-patent branded and generic sterile injectables and biosimilars primarily from the Specialty Care and Oncology product portfolios to a new Hospital and Biosimilars product portfolio within our Biopharma reportable segment. See Note 13A above. We reclassified prior period amounts to conform to the current period presentation
[2] See Note 13A above.
[3] PC1 includes revenues from our contract manufacturing and our active pharmaceutical ingredient sales operation, as well as revenues related to our manufacturing and supply agreements with legacy Pfizer businesses/partnerships. Also includes revenues associated with the wind-down of our former Pfizer Ignite operating segment, which were not material in both periods presented. We reclassified prior period amounts to conform to the current period presentation.
[4]
(b)Reflects alliance revenues and royalty revenues.
[5] Primarily reflects alliance revenues and royalty revenues.
[6] Reflects product revenues and royalty revenues.
[7] Erbitux® is a registered trademark of ImClone LLC.
[8] Reflects alliance revenues.
[9] Biosimilars are highly similar versions of approved and authorized biological medicines. Oncology biosimilars primarily include Ruxience, Zirabev, Retacrit, Trazimera and Nivestym.